The DOI matches its Crossref record; 112 of the 114 references it cites were found in a registry or an index.
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
Open accessAbstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinically, GLP-1 RAs are indicated for the treatment of type 2 diabetes (all) and obesity (liraglutide and semaglutide only) and have beneficial effects on patient-important outcomes such as weight loss, cardiovascular and kidney events, hepatic steatosis, and mortality.5,7–9,11,30”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By contrast, modern treatment guidelines for type 2 diabetes 154 and essential hypertension 155 (also nutrition related chronic diseases), do recommend a stepped care approach to pharmacotherapy.”
From Effectiveness and safety of drugs for obesity (2024) · cites this paper as [154]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“As a result, GLP-1 RAs are contraindicated for patients with a personal or family history of MTC or those with multiple endocrine neoplasia syndrome type 2.8,17,22”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredIn the citing paper
“However, a 5% weight reduction is insufficient to improve many aspects of health, and greater weight losses confer greater benefits, 23,82,83 with some data suggesting that there may be a threshold effect for reduction in some important comorbidities such as CVD and diabetes remission.[84][85][86]”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 1,039
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Self-citation
Research works printed but not linked: 1
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
Cited by
Sorted by citations
Items 201–300 of 852
Kaufmann, G. T., Hyman, M. J., Gonnah, R., Hariprasad, S. M., & Skondra, D. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.11.22 · Cited by 14
Atkinson, M., Gharti, P., & Min, T. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.2.7 · Cited by 19
Tirzepatide for type 2 diabetes
Anderson, S. L., & Marrs, J. C. (2023) · Drugs in Context · doi:10.7573/dic.2023-6-1 · Cited by 13
Cortez, B. N., Pan, H., Hinthorn, S. J., Sun, H., Neretti, N., Gloyn, A. L., & Aguayo‐Mazzucato, C. (2023) · GeroScience · doi:10.1007/s11357-023-01009-8 · Cited by 14
Hooshmand Gharabagh, L., Shargh, A., Mohammad Hosseini Azar, M. R., & Esmaeili, A. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102279 · Cited by 13
Emerzian, S. R., Jóhannesdóttir, F., Yu, E. W.-Y., & Bouxsein, M. (2024) · JBMR Plus · doi:10.1093/jbmrpl/ziae003 · Cited by 13
Kerr, D. E., RAJPURA, J. R., & Namvar, T. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s436540 · Cited by 13
Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes
Andraos, J., Smith, S. R., Tran, A., & Pham, D. Q. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01406-6 · Cited by 18
Brixner, D. I., Edelman, S. V., Sieradzan, R., & Gavin, J. R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01598-3 · Cited by 14
Arici, M., ALTUN, B., Araz, M., Atmaca, A. A., Demir, T., Ecder, T., Güz, G., Yavuz, D. G., Yildiz, A., & Yilmaz, T. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1384454 · Cited by 16
Sawamura, T., Mizoguchi, R., Ohmori, A., Kometani, M., Yoneda, T., & Karashima, S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01472-w · Cited by 17
Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review
Prentza, V., Pavlidis, G., Ikonomidis, I., Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Thymis, J., Palaiodimou, L., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195786 · Cited by 14
Fiore, V., Carbotta, G., Barraco, S., Falasca, P., Aricò, C. N., & Barucca, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16174 · Cited by 16
He, L., Li, J., Cheng, X., Luo, L., & Huang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1509561 · Cited by 13
Garvey, W. T., Cohen, R. M., Butera, N. M., Kazemi, E. J., Younes, N., Rosin, S. P., Suratt, C. E., Ahmann, A., Hollander, P. A., Krakoff, J. A., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1782 · Cited by 14
Thomas, A. M., Lamb, K., & Howard, O. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.06.003 · Cited by 12
Alghamdi, A., Alsaeddi, A., Malki, H., & Alsaedi, A. A. (2023) · Cureus · doi:10.7759/cureus.44644 · Cited by 16
The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells
Altabas, V., Radošević, J. M., Špoljarec, L., Uremović, S., & Bulum, T. (2023) · Biomedicines · doi:10.3390/biomedicines11113051 · Cited by 12
Re-emergence of a forgotten diabetes complication
Dağdeviren, M., Akkan, T., & Ertuğrul, D. T. (2024) · Turkish Journal of Emergency Medicine · doi:10.4103/tjem.tjem_110_23 · Cited by 12
Riester, M. R., Zullo, A. R., Joshi, R., Daiello, L. A., Hayes, K. N., Ko, D., Kim, D. H., Munshi, M. N., & Berry, S. D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15682 · Cited by 13
Kim, N. H., Moon, J. S., Lee, Y., Cho, H., Kwak, S. H., Lim, S. K., Moon, M. K., Kim, D., Kim, T. H., Ko, E., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15705 · Cited by 13
Lv, L., Brady, B. L., Xie, L., Guevarra, M., & Turchin, A. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.06.013 · Cited by 14
Wimmer, M. I., Bartolomaeus, H., Anandakumar, H., Chen, C., Vecera, V., Kedziora, S. M., Kamboj, S., Schumacher, F., Pals, S., Rauch, A., et al. (2024) · Acta Physiologica · doi:10.1111/apha.14226 · Cited by 12
Vergani, M., Cannistraci, R., Perseghin, G., & Ciardullo, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206225 · Cited by 12
Talebi, R., Fortes, B. H., Yu, F., Coleman, A. L., & Tsui, I. (2025) · Retina · doi:10.1097/iae.0000000000004507 · Cited by 14
Hsu, S.-H., Tang, K.-P., Lin, C.-H., Chen, P., & Wang, L. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1066633 · Cited by 17
Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism
Iqbal, N., Ambery, P., Logue, J., Mallappa, A., & Sjöström, C. D. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110669 · Cited by 13
Wallach, J. D., Deng, Y., Polley, E. C., Dhruva, S. S., Herrin, J. S., Quinto, K., Gandotra, C., Crown, W. H., Noseworthy, P. A., Yao, X., et al. (2023) · Clinical Trials · doi:10.1177/17407745231193137 · Cited by 12
Kamrul-Hasan, A. B. M., Talukder, S. K., Nagendra, L., Alam, M. S., Aalpona, F. T. Z., Dutta, D., & Selim, S. (2023) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_26_23 · Cited by 12
SEA 2024 Standards for Global Control of Vascular Risk
Mostaza, J. M., Pintó, X., Armario, P., Masana, L., Real, J. T., Valdivielso, P., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.06.001 · Cited by 11
Luo, Y., Xia, Y., Gong, X., Hao, M., Wei, Q., & Liao, L. (2026) · BMC Ophthalmology · doi:10.1186/s12886-025-04559-x · Cited by 15
SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes
Jensen, S. K., Heide‐Jørgensen, U., Andersen, I. T., Bonnesen, K., Fu, E. L., Thomsen, R. W., & Christiansen, C. F. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.7409 · Cited by 13
McAdam‐Marx, C., Ruiz‐Negrón, N., Sullivan, J. M., & Tucker, J. M. (2023) · Health Services Research · doi:10.1111/1475-6773.14152 · Cited by 11
Almazan, E., Schwartz, J. L., & Gudzune, K. A. (2023) · Clinical Obesity · doi:10.1111/cob.12609 · Cited by 12
Diagnosis and management of gestational diabetes mellitus guidelines by DIPSI (Revised)
Seshiah, V., Balaji, V., Chawla, R., Gupta, S., Jaggi, S., Anjalakshi, C., Divakar, H., Banerjee, S., Bhavatharini, N., & Thanawala, U. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01222-3 · Cited by 13
Metabolomics in diabetes mellitus: clinical insight
Aleidi, S. M., Fahmawi, H. A., Masood, A., & Rahman, A. M. A. (2023) · Expert Review of Proteomics · doi:10.1080/14789450.2023.2295866 · Cited by 13
Iwakura, K., Onishi, T., Okamura, A., Koyama, Y., Tanaka, N., Okada, M., Fujii, K., Seo, M., Yamada, T., Yano, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-52101-8 · Cited by 11
Urva, S., Levine, J. A., Schneck, K. B., & Tang, C. C. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2322072 · Cited by 11
Su, Y., Hsieh, P.-C., Lai, E. C., Lin, Y.-C., & Lin, Y.-C. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101545 · Cited by 12
Alternative therapeutic strategies in diabetes management
Annicchiarico, A., Barile, B., Buccoliero, C., Nicchia, G. P., & Brunetti, G. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i6.1142 · Cited by 12
Candido, R., Loreto, C. D., Desenzani, P., Pantanetti, P., Romano, C., Settembrini, S., Solerte, S. B., & Fadini, G. P. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01625-3 · Cited by 12
Yland, J. J., Huybrechts, K. F., Wesselink, A. K., Straub, L., Chiu, Y., Seely, E. W., Patorno, E., Bateman, B. T., Mogun, H., Wise, L. A., et al. (2024) · Diabetes Care · doi:10.2337/dc23-2056 · Cited by 11
State Out-Of-Pocket Caps On Insulin Costs: No Significant Increase In Claims Or Utilization
Anderson, K. E., Chaiyakunapruk, N., Gutierrez, E. J., Schmutz, H. W., Rose, M. R., Brixner, D. I., & McQueen, R. B. (2024) · Health Affairs · doi:10.1377/hlthaff.2024.00118 · Cited by 11
Grandhi, N., Liu, L., Wang, M., Thomas, T. S., Schoen, M. W., Sanfilippo, K. M., Gao, F., Colditz, G. A., Carson, K. R., Janakiram, M., et al. (2024) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkae095 · Cited by 12
Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system
Xiao, Y., Zhou, M., & Xiao, W. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02415-w · Cited by 12
Štuhec, M., Gazdag, A. G., Cuk, Z., Oravecz, R., & Batinić, B. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1473832 · Cited by 11
Cho, Y. K., Kim, S., Kim, M., Lee, W. J., Kim, Y.-J., & Jung, C. H. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101605 · Cited by 11
Laursen, H. V. B., Jørgensen, E. P., Vestergaard, P., & Ehlers, L. H. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01268-5 · Cited by 13
Guarnotta, V., Emanuele, F., Salzillo, R., Bonsangue, M., Amato, C., Mineo, M. I., & Giordano, C. S. D. S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1248985 · Cited by 11
Cipriani, C., Lauriero, G., Tripepi, G. L., Ferrari, S., Bover, J., Ravera, M., Barbuto, S., Cianciolo, G., Nicola, L. D., Brandi, M. L., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237260 · Cited by 11
Wawrzak-Pienkowska, K., Pienkowski, T., Golonko, A., Krupa, A., Warpechowski, M., Płoński, A. F., Mojsak, P., Daniluk, J., Dâbrowski, A., & Kurek, K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178290 · Cited by 10
Feng, Z., Tong, W. K., Zhang, X., & Tang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1226778 · Cited by 10
Singh, A. K., Sahay, R. K., Gil, N., Tripathi, S., Khandelwal, V., Basu, I., Shembalkar, J., Srivastava, M. K., Bhatia, G., Pathak, V., et al. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01321-9 · Cited by 10
Type 2 Diabetes and Chronic Kidney Disease: An Opportunity for Pharmacists to Improve Outcomes
Neumiller, J. J., Peter, W. L. S., & Shubrook, J. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051367 · Cited by 10
Mreyoud, H., Walter, K. S., Wilpula, E., & Park, J. M. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2928 · Cited by 12
New perspectives in the management of diabetic nephropathy
Psyllaki, A., & Τζιόμαλος, Κ. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i6.1086 · Cited by 10
Elsherif, I., Jammah, A. A., Ibrahim, A. R., Alawadi, F., Sadek, I. S., Rahman, A. M., Sharify, G. E., AlFeky, A., Aldossari, K. K., Roushdy, E., et al. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.06.003 · Cited by 11
Translational research on cognitive impairment in chronic kidney disease
Wagner, C. A., Massy, Z. A., Capasso, G., Mattace-Raso, F., Pépin, M., Bobot, M., Zoccali, C., Ferreira, A. C., Hoorn, E. J., Silva, P. H. I., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae229 · Cited by 10
Mori, Y., Komura, T., Adomi, M., Yagi, R., Fukuma, S., Kondo, N., Yanagita, M., Duru, O. K., Tuttle, K. R., & Inoue, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02478-7 · Cited by 12
Singh, H., Natt, N. K., & Nim, D. K. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2459720 · Cited by 10
Nanna, M. G., Doan, Q. V., Fabricatore, A., Faurby, M., Henry, A. D., Houshmand‐Oeregaard, A., Levine, A., Navar, A. M., Scassellati Sforzolini, T., & Toliver, J. C. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16370 · Cited by 10
Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
Turkistani, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1535134 · Cited by 10
Gut Molecules in Cardiometabolic Diseases: The Mechanisms behind the Story
Inceu, A.-I., Neag, M. A., Craciun, A. E., & Buzoianu, A. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043385 · Cited by 10
Tzogiou, C., Wieser, S., Eichler, K., Carlander, M., Djalali, S., Rosemann, T. J., & Brändle, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108476 · Cited by 11
Shen, T., & Farley, J. F. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108625 · Cited by 11
Wang, P., Zhang, Y., Xu, W., He, J., Peng, L., Feng, Y., Xu, P., Chong, W., Hai, Y., Jia, L., et al. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01240-5 · Cited by 10
Weiskorn, J., & Danne, T. (2024) · Hormone Research in Paediatrics · doi:10.1159/000539120 · Cited by 12
Pieber, T. R., Leohr, J. K., Bue‐Valleskey, J. M., Juneja, R., Chien, J. Y., Syring, K. E., & Buse, J. B. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.06.007 · Cited by 10
Clinical Characterization of Data-Driven Diabetes Clusters of Pediatric Type 2 Diabetes
Abbasi, M., Tosur, M., Astudillo, M., REFAEY, A. K., Sabharwal, A., & REDONDO, M. J. (2023) · Pediatric Diabetes · doi:10.1155/2023/6955723 · Cited by 10
Mody, R., Meyer, K. L., Ward, J. M., & O’Day, K. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01470-w · Cited by 10
Ingrasciotta, Y., Vitturi, G., & Trifirò, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072113 · Cited by 10
Ganwir, P., Bhadane, R. N., & Chaturbhuj, G. U. (2024) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2024.108074 · Cited by 9
Haluzı́k, M., Taybani, Z. J., Araszkiewicz, A., Cerghizan, A., Mankovsky, B., Zuhdi, A., & Malecki, M. T. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01610-w · Cited by 10
Krishnan, A., Suryanarayanan, S., & Mansi, I. A. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241266773 · Cited by 9
Nisar, M. F., Li, M., Xu, J., & Wan, C. C. (2024) · Frontiers in Marine Science · doi:10.3389/fmars.2024.1438955 · Cited by 11
Safety profile of tirzepatide: A real-world pharmacovigilance analysis of EudraVigilance database
Khurana, A., Rabbani, S. A., El‐Tanani, M., Arora, M. K., Sharma, S., Dubey, H., Aljabali, A. A. A., & Tambuwala, M. M. (2024) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2024.101805 · Cited by 9
Siriyotha, S., Anothaisintawee, T., Looareesuwan, P., Nimitphong, H., McKay, G. J., Attia, J., & Thakkinstian, A. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-086424 · Cited by 10
Orozco‐Beltrán, D., Mata‐Cases, M., Artola‐Menéndez, S., Guisasola, F. Á., Cuenca, A. M. C., & Pérez, A. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.12.002 · Cited by 12
Pearson, E. R., Prato, S. D., Pavo, I. J., Franco, D. R., Zheng, J., Nicolay, C., Hemmingway, A., Wiese, R. J., & Kahn, S. E. (2025) · Diabetes · doi:10.2337/db25-0276 · Cited by 10
Espinoza-Hernández, F. A., Moreno-Vargas, A. D., & Andrade‐Cetto, A. (2023) · Plants · doi:10.3390/plants12102014 · Cited by 10
Ogunsanmi, D., Harrison, A., Pakker, A. R., Kovesdy, C. P., Bailey, J. E., & Surbhi, S. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.6.699 · Cited by 9
Metformin Impedes Oxidation of LDL In Vitro
Rossmann, C. R., Ranz, C., Kager, G., Ledinski, G., Köestenberger, M., Wonisch, W., Wagner, T., Schwaminger, S. P., Geronimo, B. D., Hrzenjak, A., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082111 · Cited by 9
Transient receptor potential vanilloid type 1: cardioprotective effects in diabetic models
Bao, J., Gao, Z., Hu, Y., Ye, L., & Wang, L. (2023) · Channels · doi:10.1080/19336950.2023.2281743 · Cited by 9
Semaglutide-induced Hyperemesis Gravidarum
Okeke, I. F., Camarda, A. R., Okeke, R., & Chaughtai, S. (2024) · JCEM Case Reports · doi:10.1210/jcemcr/luad167 · Cited by 10
Warren, M., Bergenstal, R. M., Hager, M., Bashan, E., & Hodish, I. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0041 · Cited by 10
Wang, Y., Fang, Y., & Vrablı́k, M. (2024) · Diagnostics · doi:10.3390/diagnostics14070733 · Cited by 9
Xie, L., Han, J., Cheng, Z., Liu, D., Liu, J., Xu, C., Sun, W., Li, Q., Bian, F., Zhang, W., et al. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13526 · Cited by 9
Costa, J. D. O., Lin, J., Milder, T. Y., Greenfield, J. R., Day, R. O., STOCKER, S. L., Neuen, B. L., Havard, A., Pearson, S., & Falster, M. O. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15597 · Cited by 9
Haas, B., Hass, M. D. S., Voltz, A., Vogel, M., Walther, J., Biswas, A., Hass, D., & Pfeifer, A. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101956 · Cited by 9
SGLT2 Inhibitors: Paradigm Shift from Diabetes Care to Metabolic Care—An Indian Perspective
KUMAR, K. M. P., Unnikrishnan, A., Jariwala, P. V., Mehta, A., Chaturvedi, R., Panchal, S., Lakhani, P., Acharya, R., & Dixit, J. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_377_23 · Cited by 10
Csatordai, M., Benkő, R., Matúz, M., Engi, Z., Csupor, D., Lengyel, C., & Doró, P. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01334-8 · Cited by 8
Schwartz, S. S., Corkey, B. E., Gavin, J. R., DeFronzo, R. A., & Herman, M. E. (2024) · BMC Medicine · doi:10.1186/s12916-024-03518-5 · Cited by 8
Ha, K. H., Shin, S., Na, E., & Kim, D. J. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14363 · Cited by 8
Gökbulut, P. (2024) · SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital · doi:10.14744/semb.2024.23697 · Cited by 8
Implementation Barriers to Evidence-Based Cardiovascular-Kidney-Metabolic Syndrome Management
Davis, G., Kim, D., Jun, M., & Kotwal, S. S. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.05.095 · Cited by 8
Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal
Gangopadhyay, K. K., & Singh, A. K. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102747 · Cited by 8
Cognitive impairment in type 2 diabetes mellitus: prospects for the use of metformin
Pashkovska, N. V. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.3.2023.1274 · Cited by 9
A beneficial role of GLP-1 receptor agonist therapy in ABCC8-MODY (MODY 12)
Nakhleh, A., Goldenberg‐Furmanov, M., Goldstein, R., Shohat, M., & Shehadeh, N. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108566 · Cited by 10
Permana, H., Soetedjo, N. N. M., Yanto, T. A., Tendean, M., Hariyanto, T. I., & Suastika, K. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2290488 · Cited by 8
Hernandez, I., Cousin, E. M., Wouters, O. J., Gabriel, N., Cameron, T., & Sullivan, S. D. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.23277 · Cited by 9
Metadata
- Authors
- ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Aroda, Vanita R.
- Bannuru, Raveendhara R.
- Brown, Florence M.
- Bruemmer, Dennis
- Collins, Billy S.
- Hilliard, Marisa E.
- Isaacs, Diana
- Johnson, Eric L.
- Kahan, Scott
- Khunti, Kamlesh
- Lyons, Sarah K.
- Perry, Mary Lou
- Prahalad, Priya
- Pratley, Richard E.
- Seley, Jane Jeffrie
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-12-12
- Volume
- 46
- Issue
- Supplement_1
- Pages
- S140-S157
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC9810476
- OpenAlex
- W4311264067
- Semantic Scholar
- f75bf88f7fa4c4c0cf940dad739ba96bb6d15d64
- Cited by
- 851
- References
- 114
- Citations by year
- 2026: 64 · 2025: 149 · 2024: 360 · 2023: 277 · 2022: 1
- FWCI
- 28.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, diabetes mellitus, antidiabetic drugs, clinical guidelines, treatment goals, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
